Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26707720 | 0.85 | CACNA1G (0.41) | HRH3KDM4EALDH1A1L3MBTL1POLB | |
| SCHEMBL21946674 | 0.82 | HRH3 (0.40) | HRH3KDM4EALDH1A1L3MBTL1TDP1 | |
| SCHEMBL24926368 | 0.82 | HRH3 (0.40) | HRH3KDM4EALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL26700706 | 0.81 | HRH3 (0.43) | HRH3KDM4EALDH1A1L3MBTL1TDP1 | |
| SCHEMBL21946394 | 0.81 | HRH3 (0.39) | HRH3KDM4EALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL16132779 | 0.80 | HRH3 (0.44) | HRH3KDM4EALDH1A1L3MBTL1TDP1 | |
| SCHEMBL25851958 | 0.80 | ALDH1A1 (0.36) | HRH3KDM4EALDH1A1L3MBTL1POLB | |
| SCHEMBL24926132 | 0.79 | HRH3 (0.41) | HRH3KDM4EALDH1A1POLBTDP1 | |
| SCHEMBL25851961 | 0.79 | KDM4E (0.36) | KDM4EALDH1A1POLBTDP1CYP2D6 | |
| SCHEMBL23594438 | 0.78 | L3MBTL1 (0.44) | HRH3KDM4EALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | HRH3 3051/4885KDM4E 2184/4885ALDH1A1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.